Clinical trial
A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.
NCT07668960 is registered in ClinicalTrials.gov with Shanghai Mianyi Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.
- Lead sponsor
- Shanghai Mianyi Biopharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- June 17, 2026
- Completion date
- December 30, 2029
- Enrollment
- 60 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
high-grade squamous intraepithelial lesions of the cervix associated with human papillomavirus (hpv) type 16 and/or hpv type 18 infection